Herpes simplex encephalitis (HSE) in children has previously been linked to defects in type I interferon production downstream of Toll-like receptor (TLR)3. In the present study, we used whole-exome sequencing to investigate the genetic profile of 16 adult patients with a history of HSE. We identified novel mutations in IRF3, TYK2 and MAVS, molecules involved in generating innate antiviral immune responses, which have not previously been associated with HSE. Moreover, data revealed mutations in TLR3, TRIF, TBK1 and STAT1 known to be associated with HSE in children but not previously described in adults. All discovered mutations were heterozygous missense mutations, the majority of which were associated with significantly decreased antiviral responses to HSV-1 infection and/or the TLR3 agonist poly(I:C) in patient peripheral blood mononuclear cells compared with controls. Altogether, this study demonstrates novel mutations in the TLR3 signaling pathway in molecules previously identified in children, suggesting that impaired innate immunity to HSV-1 may also increase susceptibility to HSE in adults. Importantly, the identification of mutations in innate signaling molecules not directly involved in TLR3 signaling suggests the existence of innate immunodeficiencies predisposing to HSE beyond the TLR3 pathway.
INTRODUCTION
Herpes simplex encephalitis (HSE) is a severe viral infection in the central nervous system (CNS) and the most common form of sporadic encephalitis in the Western countries. The incidence of HSE is estimated to 1:250 000 individuals per year with mortality rates as high as 25% even in the setting of appropriate antiviral treatment with acyclovir and with neurological deficits in half of survivors. 1 HSE is most commonly caused by herpes simplex virus type 1 (HSV-1) and occasionally by HSV type 2 (HSV-2). 2, 3 The disease peaks in childhood between the ages of 6 months and 3 years. In this group, it constitutes a rare complication of a primary infection with HSV-1, where the virus gains access to the CNS by means of the neuronal route through the trigeminal or olfactory nerves. A second increase in incidence of HSE is observed in the elderly, in whom the majority of HSE cases rather represents a reactivation of latently HSV-1-infected neurons of the trigeminal and olfactory ganglions. 1 However, because about 80% of adults are seropositive for HSV-1, neuroinvasion and establishment of CNS infection during either primary or secondary infection is a rare event, and knowledge on determinants of disease has remained sparse.
HSV is an enveloped DNA virus belonging to the α-herpesvirus subfamily and characterized by its ability to cause lytic infection in permissive cells, to establish latency and to have the potential to be neurotropic. 1 Both innate and adaptive immune responses are essential for immune control of herpes viruses, including type I interferons (IFNs), NK cells and cytotoxic T cells. [4] [5] [6] Regarding innate immune recognition of HSV-1, the virus is sensed by several pattern recognition receptors (PRRs) in a cell-type-specific manner. 4 First, there is evidence of sensing of the herpes virion,
by Toll-like receptor (TLR)2 at the cell surface. 7 Second, HSV genomic DNA is a major pathogen-associated molecular pattern, which is recognized by both endosomal TLR9 as well as a range of cytosolic DNA sensors, including RNA polymerase III, IFI16 and cGAS. [8] [9] [10] [11] [12] [13] Finally, productive replication of HSV leads to the accumulation of RNA species, such as dsRNA and higher-order RNA structures, which can be sensed either by the cytosolic RIG-ILike Receptor MDA5 or by endosomal TLR3. 2, [14] [15] [16] Interestingly, data from DNA sequencing of clinical HSV-1 isolates support the idea that genetic variations in the human population rather than the virus determines the outcome of HSV-1 infection.
The first genetic etiology of isolated HSE was reported in 2006 in two children with autosomal recessive (AR) UNC93B-deficiency. 17 This protein contributes to the translocation of endosomal TLRs, including TLRs 3, 7, 8 and 9 , from the endoplasmic reticulum to the endosomal compartment. 18 Next, autosomal dominant (AD) TLR3 deficiency was described in two unrelated HSE patients with an identical heterozygous missense mutation in TLR3. 2 Furthermore, an AR form of TLR3 deficiency has been identified on the basis of compound heterozygousity for two TLR3 alleles. 19 These studies strongly suggested a particular role for the TLR3 pathway in recognition and antiviral immunity to HSV. This hypothesis was supported by the subsequent identification of two HSE patients with deficiency of the TLR3 adapter TRIF, one of which carried an AR homozygous nonsense mutation, and the other being an AD heterozygous missense mutation resulting in complete and partial TRIF deficiency, respectively. 20 An additional adapter, TRAF3, was also added to the list of singlegene inborn errors of immunity with the description of AD TRAF3 deficiency in a patient with HSE by a mechanism involving loss of expression, loss of function and a dominant-negative effect. 21 Most recently, AD heterozygous mutations in the kinase TBK1 have been described in two unrelated children with HSE. 22 In these cases, mutations resulted in loss of function through either protein instability or loss of kinase activity. Finally, previously described immunodeficiencies with mutations in NEMO (Ectodermal dysplasia with anhidrosis and immunodeficiency) or STAT1 (Mendelian susceptibility to mycobacterial infection, MSMD) also predispose to HSE. 23 Common to the identified genetic defects is that they lead to reduced antiviral IFN responses in vitro in patient peripheral blood mononuclear cells (PBMCs), fibroblasts or immortalized B cells after HSV-1 infection or stimulation through the TLR3 pathway. However, each of the mutations only affect a small proportion of children with HSE, suggesting that predisposition may result from a collection of diverse but functionally and immunologically related single-gene defects. 24 In the present work, we collected a cohort of adult patients with a history of HSE and performed whole-exome sequencing and functional immunological studies on patient PBMCs to identify the presence of mutations in any of the molecules in the TLR3 signaling pathway previously associated to childhood HSE. Importantly, this approach allowed at broader search for functionally important mutations affecting alternative HSV-1 recognizing PRRs and IFN-inducing innate signaling pathways beyond TLR3.
RESULTS
With the aim to identify mutations in genes related to innate immunity in a cohort of adult HSE patients, we performed wholeexome sequencing (WES), initially focusing on the 204 genes in the Cartagenia Software, however, next using Ingenuity Variant Analysis, we broadened our perspective the full exome, for homozygous or compound heterozygous or rare (frequency o0.01) heterozygous variants/mutations, finally further narrowed in on 19 selected genes with more specific relevance for HSV-1 recognition and antiviral type I IFN production (full list of the 204 genes included as Supplementary Table 1 ). An overview of demographic data, medical history, clinical findings and identified mutation for each patient is listed schematically in Table 1 . Figures 1-9 and Supplementary Figure 1 and 2 show the results of the functional studies evaluating innate immune responses in patient PBMCs after stimulation with the TLR3 agonist polyinosinic-polycytidylic acid (poly(I:C)), and infection with Sendai Virus (SeV) and HSV-1. For practical reasons, sequencing and PBMC stimulation of P3, P7, P8 and P10 was performed in a separate round as compared with the 12 remaining patients, and these four patients are therefore analyzed separately and compared with the four specific age-and gender-matched controls analyzed together with these four patients. Finally, this information was compiled in Table 2 to summarize the experimental conditions according to stimulus, in which cytokine and IFN responses were significantly reduced in patient PBMCs as compared with controls. Below, the patients with identified mutations and functional PBMC responses are described in three distinct groups: (i) HSE patients with novel mutations (P1-P4), (ii) HSE patients with mutations in genes previously identified in children (P5-P10) and (iii) HSE patients with functionally impaired antiviral responses without identified genetic etiology (P11 and P12).
HSE patients with novel mutations in pathways involved in IFN induction or responsiveness (P1-P4) In this study, WES analysis identified novel mutations in molecules not previously associated with HSE in four of the patients. We discovered two different rare mutations in the transcription factor interferon regulatory factor (IRF) 3 in two unrelated patients, both young adults. P1 with the mutation Arg285Gln was recently described by us and is not discussed any further here. 25 P2 presented with HSE at the age of 34 years and suffers today from mild neurological deficits but has no history of other severe infections (Table 1) . In P2, we identified the heterozygous mutation Ala277Thr (Table 1) . After stimulation of patient PBMCs with poly(I:C), we found that P2 had a significantly reduced CXCL10 response as compared with C2 and all controls (Figures 1a-c) . Importantly, IFN-β and CXCL10 production after HSV-1 infection was significantly impaired in P2, suggesting reduced ability to control HSV-1 (Figures 1g-i) . Finally, SeV infection resulted in reduced CXCL10 production in P2 compared with both C2 and all controls (Figures 1m and n) . All together these data suggest a functionally defective antiviral IFN response to HSV and possibly to DNA and RNA ligands in P2.
In P3, we discovered a heterozygous missense mutation in the tyrosine kinase TYK2 (Ala53Thr) present downstream of the type I IFN receptor (Table 1) . P3 was a 61-year-old male when admitted with HSE and had no previous medical history suggesting primary immunodeficiency (Table 1) . After stimulation with HSV-1, PBMCs from P3 showed a significantly impaired CXCL10 response compared with both C3 and all controls (Figure 2e ) and also a significantly reduced IFNβ response to SeV compared with all controls (Figure 2g ), but no other significant differences in gene expression responses were detected between P3 and the controls in response (Figure 2 ).
Finally, we identified a rare heterozygous mutation in the RIGlike receptor signaling pathway adapter mitochondrial antiviral signaling protein (MAVS) (Ala124Val) in a young woman P4, who was 24 years old when presenting with HSE and had suffered from no other severe infections neither before nor after the episode of HSE (Table 1) . However, after stimulation with poly(I:C) or infection by SeV or HSV-1, P4 had a significantly higher response of the measured cytokines, IFN-β, CXCL10 and TNF-α, than C4 and no differences were detected between P4 and the all controls ( Figure 3 ). Taken together, no functional defect in antiviral responses was detectable in patient PBMCs, although these data do not exclude the possibility of a functionally impaired IFN response in other cell types, such as fibroblasts or neuronal cells.
Adult patients with mutations in genes previously associated with childhood HSE (P5-P10) In the present cohort of 16 HSE patients, WES analysis identified mutations in TRIF, STAT1, TLR3 and TBK1. These are molecules in the TLR3 or IFN receptor pathways previously associated with childhood HSE, although the mutations identified in the present study were at different positions than previously described. First, we identified two different heterozygous missense mutations in the TLR3 adapter molecule TRIF in P5 (Ala568Thr) and P6 (Ser160Phe) ( Table 1 ). P5 and P6 are two unrelated males with a history of HSE at an age above 60 years. Neither P5 nor P6 had suffered from any other severe viral infections, but it is notable that P6 experienced a severe genital herpes eruption a few days prior to the HSE episode, which was caused by HSV-2. In PBMCs from P5, the induction of IFN-β, CXCL10 and TNF-α was significantly impaired when stimulated with HSV-1 (Figures 4d and e) . In addition, the CXCL10 response was significantly impaired in P5 after SeV stimulation (Figure 4n ). In this experimental setup, poly (I:C) was a weak immune stimulator, and this may explain why we were not able to detect any possible impaired responses to this TLR3 agonist in P5 compared with controls (Figures 4a-c) .
In P6, we observed a significantly impaired induction of IFN-β, CXCL10 and TNF-α after poly(I:C) stimulation (Figures 5a-c) , and we also measured a significantly weaker IFN-β response after HSV-1 infection (Figure 5a ). Taken together, in both P5 and P6 with TRIF mutations, we found significantly impaired IFN-β responses after HSV-1 infection, and in the case of P6, we also (threshold:
).
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In two unrelated patients (P7 and P8), analysis of WES data identified two identical heterozygous missense mutations (Val266Ile), of unknown significance, in STAT1, a key transcription factor in the IFN signaling pathway (Table 1 ). P7 and P8 are males diagnosed with HSE in their sixties, and none of them had suffered from other severe infections. In PBMCs from P7, we found significantly decreased CXCL10 responses after HSV-1 stimulation In addition, we identified a rare mutation (Leu297Val) in TLR3 in a male P9 with a history of HSE in adult life and with severe neurological sequelae after this CNS infection (Table 1) . However, we did not detect significantly lower responses in PBMCs from P9 after HSV-1 or poly(I:C) ( Figure 8 ). As previously noted, this does, however, not exclude the existence of functionally impaired IFN responses in other cell types, particularly those present in the CNS, of P9.
Finally, the WES analysis of P10 uncovered a heterozygous missense mutation (Ile207Val) in the protein kinase TBK1. This patient was a female patient diagnosed with HSE (caused by HSV-2) at the age of 50, who had suffered from no other severe infections indicative of primary immunodeficiency (Table 1 ). In PBMCs from P10, the induction of CXCL10 and TNF-α was significantly impaired after HSV-1 infection compared with controls ( Figures 9e and f) . In surprising contrast to this, induction of IFNβ expression was significantly increased in P10 PBMCs in response to poly(I:C) and SeV (Figures 9a and g ). Thus, P10 have abnormal responses to virus infection, and the data suggest that antiviral responses to HSV-1 are specifically impaired in this patient.
Patients with decreased functional responses but no identified mutations (P11 and P12) In two other patients (P11 and P12), we did not detect any mutations in our WES analyses despite thorough and repeated bioinformatical analysis. However, intriguingly, PBMCs from P11 and P12 displayed markedly impaired immune responses to virus ( Supplementary Figures 1 and 2 ). P11 and P12 are males presenting with HSE in their fifties. Neither of them had suffered from other severe viral infections. After HSV-1 infection, we detected significantly reduced IFN-β, CXCL10 and TNFα responses in PBMCs from P11 ( Supplementary Figures 1d and f) . Similarly, stimulation with poly(I:C) resulted in significantly decreased IFN-β and CXCL10 responses compared with controls ( Supplementary Figures 1a and 1b ). An almost identical pattern was observed in P12. Again we measured significantly impaired IFN-β, CXCL10 and TNF-α responses in PBMCs from P12 after HSV-1 infection (Supplementary Figures 2d and f) , as well as significantly impaired CXCL10 and TNF-α responses after SeV Figures 2h and 2i) . Finally, among the last four patients, P13-P16, we did not identify any rare mutations predicted to be of importance and neither did we detect any impaired immune responses in patient PBMCs in functional assays of patient PBMCs (data not shown).
DISCUSSION
In the present study, we have investigated the genetic profile of 16 adult patients with a history of HSE and identified mutations that may be causing impaired antiviral responses in patient PBMCs. We identified four novel mutations in IRF3, TYK2 and MAVS, molecules involved in innate antiviral immunity, neither of which have previously been associated with HSE. Moreover, WES analysis revealed six mutations in TLR3, TRIF, TRAF3 and STAT1, genes previously associated with HSE in children but not in adults, although the mutations identified in the present study were at different positions than previously described. 2, 19, 20, 22 All discovered mutations are rare heterozygous missense mutations, the majority of which appear to have functional implications on antiviral responses to HSV-1 and other relevant ligands in patient PBMCs. We suggest that these mutations may increase susceptibility to HSE in these individuals thus contributing to the list of mutations in the genetic etiology of HSE in children as well as in adults. One of the major findings of this study was the identification of mutations in molecules not previously associated with HSE. The identification of an IRF3 mutation in P1 has recently been described by our group elsewhere and is not further discussed in the present work. 25 However, the identification of another unrelated patient, P2, with a different potentially functionally important mutation in IRF3 confirm our earlier findings and establishes IRF3 as a possible genetic etiology of HSE together with previously identified mutations in the TLR3 pathway. As IRF3 is located at a position downstream of several IFN-inducing pathways, IRF3 may be predicted to confer a broader infectious phenotype. However, this was not the case in P1 and P2 based on the medical history. Preliminary data from our group suggest that IRF3 mutations may differentially affect IFN production from distinct pathways, that is, TRIF-dependent pathways may be more profoundly interrupted than MAVS-dependent pathways. This observation may be explained by a recent report by Chen and associates 26 demonstrating a role for phosphorylation of innate immune adapter proteins MAVS, STING and TRIF in the activation of IRF3.
Another novel finding was the mutation in TYK2 present in P3. TYK2 is a tyrosine kinase and member of the JAK family and has a role in mediating antiviral responses downstream of the IL-12 receptor and type I IFN receptor.
27 TYK2 deficiency has previously been associated with primary immunodeficiencies with predisposition to cutaneous viral infection, atypical mycobacteriosis and Immunodeficiencies in adult patients with HSE N Mørk et al fungal infection, in the context of AR Hyper-IgE syndrome but also independently hereof. [28] [29] [30] Interestingly, TYK2 has not previously been associated with HSE. However, given that TYK2 acts downstream of the type I IFN receptor, and has been associated with cutaneous herpes infection, it seems biologically plausible that TYK2 deficiency may also increase susceptibility to HSV infection in the CNS. In P3 with the TYK2 mutation, we found impaired CXCL10 responses to HSV-1. This is in agreement with CXCL10 being an IFN-stimulated gene, the expression of which is partly driven by IFN signaling, and therefore, CXCL10 induction would be predicted to be reduced in the setting of impaired type I IFN receptor signaling due to mutation in TYK2. It is notable that P3 did not report infections suggestive of hyper-IgE syndrome, such as staphylococcal or fungal infections nor a predisposition to other severe viral infections.
The mutation in MAVS represents yet another mutation not previously linked to HSE. MAVS functions as an adapter molecule downstream of the intracellular dsRNA receptors RIG-I and MDA5, resulting in the activation of both NF-κB and IFN-inducing pathways. 31 Results from MAVS-deficient mice have demonstrated that MAVS is the sole adapter from RIG-I and MDA5 and has an essential role in induction of type 1 IFN in response to dsRNA and poly(I:C). 32 Furthermore, one report suggests that MAVS interacts with TRIF and hereby also influences TLR3-mediated immune responses. 33 However, we did not detect abolished or impaired IFN responses in PBMCs from P4, although this does not exclude the existence of functionally impaired IFN responses in other cell types, particularly those present in the CNS. 34 The identification of a mutation in a molecule with a central position in innate immune signaling in an adult HSE patient is potentially interesting, because it leaves open the possibility that molecules involved in innate immune responses besides those within the TLR3 signaling pathway may also have a significant function in antiviral defenses operating to prevent HSV-1 neuroinvasion.
To date, innate immunodeficiencies in TLR3 signaling pathways have only been described in children, but whether a similar essential role of innate immunity to HSV and HSE exists in adults, where the pathogenesis may differ by mostly involving secondary HSV-1 reactivation rather than primary infection, has not been clarified. 35 The latter aspect was the reason we decided to focus on an adult cohort of HSE patients in the present study, which is the first to document genetic defects in the TLR3-IFN pathway in adult HSE patients. In our cohort of 16 adult HSE patients, we identified mutations in several molecules previously associated with childhood HSE in the TLR3 signaling pathway, including TRIF (P5 and P6), TLR3 (P9) and TBK1 (P10) 2, 19, 20, 22 as well as STAT1 (P7 and P8). 36 TRIF is an adapter in MyD88-independent signaling pathways and the only adapter protein associated with TLR3, from where it initiates IFN-β production. 31 Mutations in TRIF in other positions of the molecule have previously been found in two HSE patients, one of which carried an AR homozygous nonsense mutation (Arg141X), and the other being an AD heterozygous missense mutation (Ser186Leu), resulting in complete and partial TRIF deficiency, respectively. 20 AD TLR3 deficiency had previously been described in two unrelated HSE patients with an identical heterozygous missense mutation (Pro554Ser) in TLR3, 36 and an AR form of TLR3 deficiency has been identified on the basis of compound heterozygousity for two TLR3 alleles (Pro554Ser) and (Glu746X). 19 In addition, AD heterozygous mutations in TBK1 have been described in two unrelated children with HSE by a mechanism involving loss of function through either protein instability (Asp50Ala) or loss of kinase activity (G159A). 22 In addition, we identified two heterozygous missense mutations (Val266Ile) in the signal transducer STAT1 (Table 1) . Intriguingly, the Val266Ile variant we found in STAT1 have recently been published as a dominant gain-of-function mutation leading to an immune dysregulation-polyendocrinopathy-enteropathy-X-linkedlike syndrome (IPEX), while the patients described here (P7 and P8) did not suffer from IPEX, suggesting that other factors may affect the phenotype. 37 A role of homozygous STAT1 mutations in two patients with mycobacterial disease and disseminated viral disease, including HSE has also previously been described. 36 In contrast, several STAT1 gain-of-function mutations have been found to result in abolished Th17 responses thereby causing chronic mucocutaneous candidiasis. 38 Whereas patients with These results lead us to suggest that single-gene inborn errors of immunity may also have functional impact in adults, at least in some cases. However, whether the patients with identified mutations in TLR3 signaling molecules described in the present study suffered from HSE due to primary or secondary infection cannot be determined with certainty on the basis of the medical history. Interestingly, in the case of P6, there was a history of severe genital herpes infection preceding the HSE episode, suggesting primary HSV infection underlying HSE in this patient. For the remaining patients (P5 and P7-P10) with mutations in previously identified molecules related to childhood HSE, there was no apparent history of recurrent labial or genital herpes. Unfortunately, no HSV-1/2 serological measurements were carried out at the time of hospitalization. Altogether, it does not seem entirely clarified whether the pathogenesis of viral neuroinvasion and establishment of CNS infection during primary versus secondary HSV-1 infection differs in such significant ways that it should be decisive for whether the presence of TLR3-IFN defects will be clinically important. , d, g ), CXCL10 (b, e, h) or TNFα (c, f, i) mRNA by real-time qPCR. Cytokine levels were normalized to GAPDH and TBP and compared with age-and gender-matched healthy control or the pooled results of a total of 12 healthy controls. Data are shown as a box plot with median, first and third quartiles. Error bars represent minimum and maximum values. The pooled controls are illustrated as the 5-95% population, with outliers shown as independent dots. The non-parametric Mann-Whitney ranked sum test was used to evaluate statistical significance between the groups.
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In two patients (P11 and P12), we did not identify any mutations that passed the threshold for justifying a suggestion of a relevant disease-causing mutation based on our criteria for rarity, comparison with publicly available databases and filtering through relevant bioinformatical software as described in the Methods section. However, impaired responses to virus and/or TLR ligands present in patient PBMCs strongly suggest that there may be a functional defect in HSV-induced antiviral IFN and IFNstimulated gene induction in these patients. Such defect with a genetic origin may be identified in the future, made possible by novel software for data analysis or along with new insights into immune receptors, signaling pathways or cellular processes involved in generating antiviral responses. Furthermore, even though exome sequencing covers the major part of expressed genes, not all regions are fully covered and potentially important miRNAs are not covered either. Thus, future approaches as the cost of NGS decreases may involve full genome sequencing along with RNAseq to discover other areas of interest as well as dysregulation of gene expression.
In this study, some degree of heterogeneity was observed between the ability to generate antiviral immune responses to different viruses and between different patients. This is in agreement with previously published results by us and others, 17, 19, 25 probably reflecting the differences between viruses in their sensing by different PRRs and utilization of different signaling pathways/molecules. For example, HSV-1 is sensed by many different PRRs, including TLR3 and TLR9 and the cytosolic DNA sensors cGAS and IFI16, whereas SeV is recognized mainly by the RIG-like receptor RIG-I, and finally, poly(I:C) is a synthetic pathogen-associated molecular pattern mainly stimulating TLR3 signaling. 39 Therefore, functional outcome, that is, IFN production, will be a reflection of the signaling molecules involved, and mutations in different molecules will be predicted to affect these signaling pathways in a differential manner. Finally, a certain degree of biological difference between individuals exists with respect to the magnitude and duration of antiviral responses when challenged with viruses or PRR ligands.
Another unresolved question relates to the proportion of cases of HSE that can be directly attributed to single-gene inborn errors of immunity. In the present study, we identified mutations with a possible association to HSE in 10 of 16 patients (corresponding to about 62%), which may seem as a large fraction. A French study found five different mutations in TLR3 and UNC93B in a cohort of a total of 85 children collected throughout a 20-year period, suggesting that these specific mutations are involved in only a minority of affected children. 40 However, as the French study did not examine other relevant signaling components than TLR3 and UNC93B, the two only known genetic etiologies of HSE at the time, additional disease-causing mutations in other IFN-inducing immune components may remain unidentified in that specific cohort. The most recent analysis of the genetic etiology of HSE has been published by Zhang and colleagues. 41 In a collection of 120 children with HSE, these authors identified mutations in TLR3 or molecules belonging to the TLR3 signaling pathway in about 12%. All together, the WES approach taken in our study identifies a larger fraction of mutations than previously reported. However, the relevance of these mutations is only possible to judge through functional cellular and immunological studies of patient PBMCs, fibroblasts and other cell types, particularly IPSCs. It should also be noted that although most of the molecules in the TLR3 pathway were previously associated to HSE in children, the specific mutations identified in these molecules in the present study were novel. Finally, our study only included patients surviving a previous episode of HSE, but important information on the association between IFN-related immunodeficiencies and HSE may be gained from genetic analysis of material from deceased patients who died because of HSE. Unless mortality was due to lack or delay in Acyclovir treatment, the range, frequency and severity of mutations may be hypothesized to be even more extensive in these patients who suffered a particular fulminating and devastating HSV CNS infection.
Despite major advances in our understanding of HSE pathogenesis and the role of innate immunity in antiviral defenses to HSV-1 in the CNS, several central questions remain. Given that antiviral immunity to HSV-1 has been described to involve multiple PRRs, such as DNA sensors, TLRs and RIG-like receptors and their cognate signaling pathways, as well as autophagy, mutations in all of these molecules may theoretically predispose humans to HSE. 4, 42 In the present study, we have identified novel mutations in innate molecules within and beyond the TLR3 pathway, which we suggest may increase the susceptibility to HSE. Furthermore, our study strongly suggests that mutations in the TLR3 signaling pathway previously identified in childhood HSE are also of functional significance in adults and may confer a significantly increased susceptibility to HSE in all age groups. However, owing to redundancy at the cellular level and incomplete penetrance of the clinical phenotype, it remains a complex and in some cases a difficult task to evaluate the precise functional significance of a given mutation in any single patient. Future studies are required to reveal to what extent the specific mutations identified in the present study will be present within additional HSE patients and proven to be causal. We believe that it is important to consider that these individual mutations highlight a key pathway, through which viral infection can produce a rare but consistent pathology, when a specific host defense pathway is disrupted in one or more of its constituents. At the therapeutic level, it remains unresolved within the field, whether identified mutations associated with increased susceptibility to HSE will require genetic testing and counseling of family members, and whether lifelong acyclovir prophylaxis may be justified in light of recent evidence of increased recurrence risk in HSE patients with these mutations.
MATERIALS AND METHODS

Patients and controls
The patient group consisted of patients aged 15 years and above with a history of HSE hospitalized at the Department of Infectious Diseases, Aarhus University Hospital Skejby. The patients were all of Danish 
Ethics
Permission to perform this project was obtained from the Regional Ethics Committee (permission number: 1-10-72-586-12). All patients provided informed written consent.
Blood samples
Blood samples from the patients were used for isolation of PBMCs and for WES. Blood samples from the control group were only used for PBMC isolation. PBMCs were purified from EDTA blood by a Ficoll density gradient and stored in liquid nitrogen.
Whole-exome sequencing (WES)
Genomic DNA was isolated from 1 ml EDTA stabilized blood using MagNA Pure Compact Nucleic Acid Isolation Kit I -Large Volume (Roche Applied Science, Penzberg, Germany). TruSeq DNA sample preparation was performed according to the manufacturer's recommendations (Illumina, San Diego, CA, USA) on a Caliper Sciclone robot (Perkin Elmer, Waltham, MA, USA), targeting of exomes with SeqCap EZ Human Exome Library v3.0 (Roche) and purification of libraries was performed using a Caliper Zephyr robot. Libraries were quantified using Kapa quantification (Kapa Biosystems, Wilmington, MA, USA) and sequencing was performed on HiSeq, paired end 2X101 bp indexed. Adapters were identified and removed, reads were mapped to hg19 using BWA mem. PCR and optical duplicates were identified and marked. The alignment file (bam) was realigned using GATK to refine the alignment; especially around indels at the ends of reads. The alignment was recalibrated using GATK. Single nucleotide polymorphisms were called using HaplotypeCaller from the GATK package. Variant call files were initially filtered using Cartagenia (Markham, ON, Canada) on the basis of frequency in the NHLBI Exome Sequencing Project (ESP) Exome Variant Server (ESP6500) and 1000 Genome (o1%), through evaluation by prediction tools (SIFT, PolyPhen-2 and MutationTaster) and filtered using a list of 204 genes known to be involved in immunodeficiency or involved in relevant pathways (Supplementary Table 1 genes directly involved in HSV recognition and IFN induction were further focused on, these are labeled with an asterisk). The list was generated on the basis of genes present in the IDBases (http://structure.bmc.lu.se/ idbase/ 43 along with a search in the KEGG Pathway Database. 44, 45 Secondly, the WES data were analyzed using Ingenuity Variant Analysis and filtering as indicated in Supplementary Figure 3 . Importantly, we excluded the existence of rare homozygous and compound heterozygous mutations in relevant genes. Identified mutations were analyzed by the Integrative Genomics Viewer (IGV) on the basis of BAM files and further characterized by CADD score (scaled C-scores or Phred values are shown in Table 1 ). Scores above 10 belong to the 10% most deleterious, above 20 belong to the 1% most deleterious variants, 46 and finally confirmed by Sanger sequencing.
PBMC stimulations
Frozen PBMCs were thawed in 50 ml tubes in 20 ml preheated media (RPMI-1640 w/L-Glutamine, Biowest (Nualle, France), supplemented with 10% heat-inactivated fetal bovine serum, Life Technologies (Carlsbad, CA, USA), 1% penicillin/streptomycin) and spun down at 350 g in 10 min. PBMCs were distributed into 24-well plates at a concentration of 10 6 cells per 300 μl media. Cells were incubated overnight at 37°C under an atmosphere containing 5% CO 2 and infected in duplicates with SeV Cantell Strain (VR-907 from ATCC, Mannassas, VA, USA) 1:500 or HSV-1 (multiplicity of infection 9), or stimulated by the TLR3 agonist poly(I:C) at 50 μg ml − 1 or left untreated. Cells were incubated for 6 h before harvest and RNA isolation. For practical reasons, sequencing and PBMC stimulation of P3, P7, P8 and P10 was performed in a separate round as compared with the 12 remaining patients, and these 4 patients are therefore analyzed separately and compared with 4 specific age-and-gender-matched controls analyzed together with these 4 patients only.
RNA isolation and reverse transcription 
Real-time qPCR with TaqMan probes
Expression levels of IFN-β, the IFN-stimulated gene, CXCL10 (IP10), TNFα and the two household genes, GAPDH and TBP, were analyzed by real-time qPCR using TaqMan probes. Real-time-qPCR was performed in two steps ((i) reverse transcription, (ii) qPCR); the second step in the qPCR was performed on the synthesized cDNA using PerfeCTa ToughMix II (Quanta BioSciences, Gaithersburg, MD, USA). cDNA (1.8 μl) was used in each well with additionally 18.2 μl ToughMix (Quanta BioSciences). TaqMan probes were IFNB1 -Hs01077958, CXCL10 -Hs01124251, TNF -Hs01113624 (Life Technologies), GAPDH -Hs02758991 and TBP -Hs00427620. qPCR program: 1 cycle at 95°C for 10 min, 45 cycles at 95°C in 30 s and 60°C for 1 min. Every sample was run in technical duplicates.
Statistics
Data sets were analyzed for variance and normal distribution. The groups compared statistically exhibited similar variation. The Mann-Whitney rank t-test was used to determine statistical significance. All graphs show the calculated median and the 5-95 percentiles for all data points. Not significant (n.s.), P40.05, *P ⩽ 0.05, **P ⩽ 0.01, ***P ⩽ 0.001, ****P ⩽ 0.0001.
